Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Non-Human Primate Safety Pharmacology Studies for Intrathecally Delivered AAV9 Therapies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Non-Human Primate Safety Pharmacology Studies for Intrathecally Delivered AAV9 Therapies

Non-Human Primate Safety Pharmacology for Intrathecal AAV9 Gene Therapies

CELL & GENE | RNA | BIOLOGICS

A stylized 3D rendering of a DNA double helix, composed of light-colored spheres on a translucent blue backbone, set against a soft-focus, light blue background.

Executive Summary: Intrathecal administration of AAV9 vectors for central nervous system (CNS) gene therapy presents a significant translational challenge: managing unintended vector biodistribution to peripheral tissues, particularly the liver. This can lead to dose-limiting toxicity that obscures the therapeutic window. Our non-human primate (NHP) safety pharmacology programs are designed to address this specific issue, incorporating advanced strategies to mitigate peripheral exposure and generate high-fidelity data packages for regulatory submission. We leverage anatomically and immunologically relevant NHP models to accurately predict human outcomes, supporting an average 18-24 month IND timeline.

Frequently Asked Questions (FAQ)

    Why are NHP models required for intrathecal AAV9 safety studies?

    A: NHP models possess a CNS anatomy, cerebrospinal fluid (CSF) dynamics, and an immune system that closely recapitulate human biology. This fidelity is necessary for accurately assessing vector distribution, transduction efficiency in target CNS regions, and potential immunogenicity following intrathecal delivery.

    What is the primary safety concern with high-dose intrathecal AAV9?

    A: The primary concern is vector leakage from the CSF into systemic circulation, leading to non-target tissue biodistribution. The liver, due to its high perfusion and fenestrated endothelium, is particularly susceptible to transduction, which can result in dose-dependent adverse liver findings.

    How can peripheral liver transduction be minimized?

    A: One effective strategy involves the co-administration of intravenous immunoglobulins (IVIG). Key preclinical studies show that passive transfer of AAV-neutralizing antibodies can effectively sequester vector particles in the periphery, significantly reducing liver transduction without compromising gene delivery to the CNS.

    What are the key endpoints in these NHP safety studies?

    A: Key endpoints include in-life clinical observations, CSF analysis for biomarkers and vector shedding, serum chemistry to monitor organ function, and comprehensive terminal histology and vector biodistribution analysis in all relevant CNS and peripheral tissues.

Characterizing Intrathecal AAV9 Biodistribution in NHP Models

Achieving targeted gene delivery to the CNS while avoiding systemic exposure is a primary objective for many AAV9-based therapeutics. The intrathecal route of administration is designed for direct CNS targeting, yet the complex interplay between CSF flow and vascular drainage often results in vector escaping into the periphery. Our study designs focus on quantifying this phenomenon and evaluating strategies to improve the safety profile.

A core component of our approach involves a deep understanding of vector behavior. We leverage our team’s extensive experience, which includes key personnel from the former UPenn Vector Core, to ensure every study is built on a foundation of robust vector science.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A close-up of a scientist in blue gloves gently holding a small, white laboratory mouse, likely in a research setting.

A promotional graphic for Franklin BioLabs showcasing a list of their notable scientific publications in preclinical and translational research.

Mitigating Systemic Exposure and Improving the Therapeutic Index

Translational insights from peer-reviewed literature inform our advanced study designs. For instance, evidence suggests that pre-treatment with IVIG can neutralize circulating AAV particles, effectively shielding the liver from unintended transduction (PMID: 36320416). This method enhances the safety profile by decoupling the CNS therapeutic dose from peripheral toxicity, a significant step in de-risking a clinical candidate.

Our programs provide the rigorous data needed to characterize these effects. We generate comprehensive biodistribution and toxicology data packages within our >100,000 sq ft GxP-compliant facility, which have supported a 100% IND success rate for our clients since 2019. (The Franklin Biolabs brand launched in 2024).

Commitment to Animal Welfare

Our programs are fully accredited by AAALAC and operate in compliance with USDA regulations.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities